<html>
<head>
    <script language="JavaScript" src="http://code.jquery.com/jquery-1.4.4.js"></script>
    <script language="JavaScript" src="../js/pie.js"></script>
    <script language="JavaScript" src="../js/browser_adjust.js"></script>
    <script language="JavaScript" src="../js/search.js"></script>


    <script type="text/JavaScript">
    <!--

    var array = [[10.9966329023, "../topics/{product,_candidate,_development}.html", "{product,_candidate,_development}"], [7.5505578333, "../topics/{stock,_price,_share}.html", "{stock,_price,_share}"], [7.4591842677, "../topics/{property,_intellectual,_protect}.html", "{property,_intellectual,_protect}"], [2.7347991285, "../topics/{control,_financial,_internal}.html", "{control,_financial,_internal}"], [1.923472617, "../topics/{product,_liability,_claim}.html", "{product,_liability,_claim}"], [1.8120337717, "../topics/{stock,_price,_operating}.html", "{stock,_price,_operating}"], [1.7970509266, "../topics/{acquisition,_growth,_future}.html", "{acquisition,_growth,_future}"], [1.7390901734, "../topics/{personnel,_key,_retain}.html", "{personnel,_key,_retain}"], [1.7319476419, "../topics/{cost,_regulation,_environmental}.html", "{cost,_regulation,_environmental}"], [1.6936719583, "../topics/{customer,_product,_revenue}.html", "{customer,_product,_revenue}"], [1.655532543, "../topics/{regulation,_government,_change}.html", "{regulation,_government,_change}"], [1.6076362667, "../topics/{cost,_operation,_labor}.html", "{cost,_operation,_labor}"]];
    var elements = generate_pie_elements(array);
    var piec = null;
    function init() {
        browser_adjust();
        
        // create pie chart
        piec = new PieChart(elements);
        piec.initialize();

    }

    function highlight(i) {
        piec.highlight(i);
    }
    
    function unhighlight() {
        piec.unhighlight();
    }
    //-->
    </script>

    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
    
    <title>1341843--3/27/2008--POLYMEDIX_INC</title>

    <link href="../styling.css" rel="stylesheet" type="text/css">
</head>

<body onLoad="init()">
<div id="navigation">
<hr noshade>
<table><tr>
    <td class="navtext">Browse&nbsp;&#x25B8;</td> 
    <td class="linked"><a>Topics</a>
      <ul> 
        <li><a href="../browse/topic-list.html">List of Terms</a></li> 
        <li><a href="../browse/topic-graph.html">Term Distributions</a></li> 
        <li><a href="../browse/topic-presence.html">Relative Presence</a></li>
      </ul> 
    </td> 
    <td class="linked"><a>Documents</a>
      <ul>
        <li><a href="../browse/doc-graph.html">Topic Distributions</a></li>
      </ul> 
    </td>
    <td class="linked"><a>Terms</a>
      <ul> 
        <li><a href="../browse/term-list.html">List by Frequency</a></li> 
        <li><a href="../browse/term-graph.html">Topic Distributions</a></li> 
       </ul> 
    </td>
    <td class="linked"><a>About</a>
      <ul>
        <li><a href="http://www.cs.princeton.edu/~blei/lda-c/">LDA</a></li>
      </ul> 
    </td>
    
    </td>
    <td></td>
    <td class="searchbar"> Search&nbsp;&#x25B8;</td>
    <td class="searchbar"><input type="text" name="search" size="20" onkeypress="handleKeyPress(event)"><span onclick="doSearch()"></span>
    </td>
</tr></table>
</div>

    <div id="top"></div>

    <h1 id="header">
        <table><tr>
            <td id="title">1341843--3/27/2008--POLYMEDIX_INC</td>
        </tr></table>

        <hr noshade>
    </h1>

    <div id="main">
        <table><tr>
            <td width="210px">
                <table class="dark">
                <tr><td><canvas id="canvas" width="200" height="200"></canvas></td></tr>
                <tr class="title">
                    <td>related topics</td>
                </tr>
                <tr class="list"><td id="{product,_candidate,_development}" onmouseover="highlight(0)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{product,_candidate,_development}.html'">{product, candidate, development}</td></tr>
<tr class="list"><td id="{stock,_price,_share}" onmouseover="highlight(1)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{stock,_price,_share}.html'">{stock, price, share}</td></tr>
<tr class="list"><td id="{property,_intellectual,_protect}" onmouseover="highlight(2)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{property,_intellectual,_protect}.html'">{property, intellectual, protect}</td></tr>
<tr class="list"><td id="{control,_financial,_internal}" onmouseover="highlight(3)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{control,_financial,_internal}.html'">{control, financial, internal}</td></tr>
<tr class="list"><td id="{product,_liability,_claim}" onmouseover="highlight(4)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{product,_liability,_claim}.html'">{product, liability, claim}</td></tr>
<tr class="list"><td id="{stock,_price,_operating}" onmouseover="highlight(5)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{stock,_price,_operating}.html'">{stock, price, operating}</td></tr>
<tr class="list"><td id="{acquisition,_growth,_future}" onmouseover="highlight(6)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{acquisition,_growth,_future}.html'">{acquisition, growth, future}</td></tr>
<tr class="list"><td id="{personnel,_key,_retain}" onmouseover="highlight(7)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{personnel,_key,_retain}.html'">{personnel, key, retain}</td></tr>
<tr class="list"><td id="{cost,_regulation,_environmental}" onmouseover="highlight(8)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{cost,_regulation,_environmental}.html'">{cost, regulation, environmental}</td></tr>
<tr class="list"><td id="{customer,_product,_revenue}" onmouseover="highlight(9)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{customer,_product,_revenue}.html'">{customer, product, revenue}</td></tr>
<tr class="list"><td id="{regulation,_government,_change}" onmouseover="highlight(10)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{regulation,_government,_change}.html'">{regulation, government, change}</td></tr>
<tr class="list"><td id="{cost,_operation,_labor}" onmouseover="highlight(11)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{cost,_operation,_labor}.html'">{cost, operation, labor}</td></tr>

                </table>
            </td>

            <td>
                <table class="light">
                <tr class="doc"><td>
                    We are a development stage company with limited operating history, which makes it difficult to evaluate our existing business and business prospects and increases the risk that the value of any investment in our Company will decline.
We have incurred losses since inception and anticipate that we will continue to incur losses for the foreseeable future.
We also expect our research and development expenses to increase in connection with the continued development and human clinical studies of our product candidates. If our product candidates are not demonstrated to be sufficiently safe and effective in clinical trials, they will not receive regulatory approval and we will be unable to commercialize them and our business and results of operations will suffer.
If we are not able to retain our current management and advisory team and attract and retain qualified scientific, technical and business personnel, our business will suffer.
Our success is dependent on the continuation of certain licensing arrangements and other strategic relationships with third parties. There can be no assurance that such relationships will continue or that we will be successful in entering into other similar relationships.
Development of our proposed product candidates is a lengthy, expensive and uncertain process, and we may terminate one or more of our development programs, which may cause our business and results of operations to suffer.
There can be no assurance that our i.v. antibiotic product candidate or any of our other eligible product candidates will be granted any of the accelerated development or approval paths by the FDA and, even if any of our product candidates receive such status, that development of the product candidate will be accelerated.
Even if regulatory authorities approve our product candidates, they may not be commercially successful.
We do not currently have sales, marketing or distribution capabilities. If we fail to effectively sell, market and distribute any product candidate for which we receive regulatory approval, our business and results of operations will suffer.
We may suffer losses from product liability claims if our products cause harm to patients.
Due to our reliance on third-party manufacturers and suppliers, we may be unable to implement our manufacturing and supply strategies, which would materially harm our business.
If we make technology or product acquisitions, we may incur a number of costs, may have integration difficulties and may experience other risks that could harm our business and results of operations.
Failure to effectively manage our growth may have a material adverse effect on our business, results of operations and financial condition.
We rely on third parties to provide software necessary to the future success of our business.
Our executive officers, directors and greater than 5% holders have the ability to significantly influence matters submitted to our stockholders for approval.
Risks Related to our Intellectual Property
The obstacles to procurement and enforcement of our intellectual property and proprietary rights could harm our competitive position by allowing competitors access to our proprietary technology and to introduce competing products.
We may have to engage in costly litigation to enforce or protect our proprietary technology, which may harm our business, results of operations, financial condition and cash flows.
Our commercial success depends significantly on our ability to develop and commercialize our products without infringing the intellectual property rights of third parties.
We may be unable to protect the intellectual property rights of the third parties from whom we license certain of our intellectual property or with whom we have entered into other strategic relationships, which may harm our business.
International patent protection is particularly uncertain, and if we are involved in opposition proceedings in foreign countries, we may have to expend substantial sums and management resources.
Risks Related to our Industry
We may experience delays in obtaining required regulatory approvals in the U.S. to market our proposed product candidates.
Before we can commence clinical trials of any of our product candidates, we will need to complete preclinical research and commercial evaluation and file an IND (or foreign equivalent) with respect to such product candidate. We cannot provide assurance that we will complete this preclinical research or file an IND in a timely fashion or at all.
Because clinical trials for our product candidates will be expensive and protracted and their outcome is uncertain, we must invest substantial amounts of time and money that may not yield viable products.
If competitors develop and market products that are more effective, have fewer side effects, are less expensive than our product candidates or offer other advantages as compared to our product candidates, our commercial opportunities will be limited.
Healthcare reform measures could adversely affect our business.
Because our activities may involve the use of hazardous materials, we may be subject to claims relating to improper handling, storage or disposal of these materials that could be time consuming and costly.
Risks Related to our Common Stock
A decline in the price of our common stock could affect our ability to raise further working capital and adversely impact our ability to continue operations.
If we issue additional shares in the future, it will result in the dilution of our existing stockholders.
Trading of our stock may be restricted by the Securities Exchange Commission s penny stock regulations, which may limit a stockholder s ability to buy and sell our stock.
Financial Industry Regulatory Authority (FINRA) sales practice requirements may also limit a stockholder s ability to buy and sell our stock.
Our common stock is illiquid and the price of our common stock may be negatively impacted by factors that are unrelated to our operations.
We have never paid dividends on our common stock and do not anticipate paying any in the foreseeable future.
<p><a href="http://www.sec.gov/Archives/edgar/data/1341843/0000893220-08-000876.txt">Full 10-K form&nbsp;&#x25B8;</a></p>
                </td></tr>
                </table>
            </td>

            <td width="25%">
                <table class="dark">
                <tr class="title">
                    <td>related documents</td>
                </tr>
                <tr class="list"><td onclick="window.location.href='../docs/1341843--3-23-2009--POLYMEDIX_INC.html'">1341843--3/23/2009--POLYMEDIX_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1070698--3-16-2006--AXONYX_INC.html'">1070698--3/16/2006--AXONYX_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1172480--3-6-2009--SANTARUS_INC.html'">1172480--3/6/2009--SANTARUS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1000694--3-31-2009--NOVAVAX_INC.html'">1000694--3/31/2009--NOVAVAX_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1172480--3-4-2010--SANTARUS_INC.html'">1172480--3/4/2010--SANTARUS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1464165--5-28-2010--Neurokine_Pharmaceuticals_Inc..html'">1464165--5/28/2010--Neurokine_Pharmaceuticals_Inc.</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1305409--3-20-2006--Valera_Pharmaceuticals_Inc.html'">1305409--3/20/2006--Valera_Pharmaceuticals_Inc</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1172480--3-7-2006--SANTARUS_INC.html'">1172480--3/7/2006--SANTARUS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/707511--4-15-2009--REGENERX_BIOPHARMACEUTICALS_INC.html'">707511--4/15/2009--REGENERX_BIOPHARMACEUTICALS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/707511--3-31-2010--REGENERX_BIOPHARMACEUTICALS_INC.html'">707511--3/31/2010--REGENERX_BIOPHARMACEUTICALS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/878903--3-22-2007--ALTEON_INC_-DE.html'">878903--3/22/2007--ALTEON_INC_/DE</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1023024--3-16-2009--BIOSANTE_PHARMACEUTICALS_INC.html'">1023024--3/16/2009--BIOSANTE_PHARMACEUTICALS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1203944--10-30-2008--RAPTOR_PHARMACEUTICALS_CORP..html'">1203944--10/30/2008--RAPTOR_PHARMACEUTICALS_CORP.</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1172480--3-6-2007--SANTARUS_INC.html'">1172480--3/6/2007--SANTARUS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1035354--9-26-2008--SENESCO_TECHNOLOGIES_INC.html'">1035354--9/26/2008--SENESCO_TECHNOLOGIES_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1390478--4-15-2008--RXI_PHARMACEUTICALS_CORP.html'">1390478--4/15/2008--RXI_PHARMACEUTICALS_CORP</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1390478--3-18-2009--RXI_PHARMACEUTICALS_CORP.html'">1390478--3/18/2009--RXI_PHARMACEUTICALS_CORP</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1412067--5-6-2010--Oncothyreon_Inc..html'">1412067--5/6/2010--Oncothyreon_Inc.</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1000694--3-17-2008--NOVAVAX_INC.html'">1000694--3/17/2008--NOVAVAX_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1273013--3-6-2008--PHARMACOPEIA_INC.html'">1273013--3/6/2008--PHARMACOPEIA_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/729922--3-1-2007--OSI_PHARMACEUTICALS_INC.html'">729922--3/1/2007--OSI_PHARMACEUTICALS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/716646--6-16-2008--CLINICAL_DATA_INC.html'">716646--6/16/2008--CLINICAL_DATA_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/899923--8-12-2010--MYRIAD_GENETICS_INC.html'">899923--8/12/2010--MYRIAD_GENETICS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1390478--3-31-2010--RXI_PHARMACEUTICALS_CORP.html'">1390478--3/31/2010--RXI_PHARMACEUTICALS_CORP</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1412067--3-30-2009--Oncothyreon_Inc..html'">1412067--3/30/2009--Oncothyreon_Inc.</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1328003--3-29-2010--Redpoint_Bio_CORP.html'">1328003--3/29/2010--Redpoint_Bio_CORP</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/911216--9-29-2008--PALATIN_TECHNOLOGIES_INC.html'">911216--9/29/2008--PALATIN_TECHNOLOGIES_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1003642--3-12-2009--IMPAX_LABORATORIES_INC.html'">1003642--3/12/2009--IMPAX_LABORATORIES_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/729922--2-28-2008--OSI_PHARMACEUTICALS_INC.html'">729922--2/28/2008--OSI_PHARMACEUTICALS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/353482--9-27-2006--VIRAGEN_INC.html'">353482--9/27/2006--VIRAGEN_INC</td></tr>

                </table>
            </td>
        </tr></table>
    </div>

    <div id="footer">
        <br>
        <hr noshade>
    </div>
</body>
</html>
